148 related articles for article (PubMed ID: 23957015)
1. The role of adrenomedullin in the renal NADPH oxidase and (pro)renin in diabetic mice.
Hayashi M; Tojo A; Shimosawa T; Fujita T
J Diabetes Res; 2013; 2013():134395. PubMed ID: 23957015
[TBL] [Abstract][Full Text] [Related]
2. Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse.
Liu GC; Fang F; Zhou J; Koulajian K; Yang S; Lam L; Reich HN; John R; Herzenberg AM; Giacca A; Oudit GY; Scholey JW
Diabetologia; 2012 Sep; 55(9):2522-32. PubMed ID: 22653270
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidic acid receptor 1 inhibitor, AM095, attenuates diabetic nephropathy in mice by downregulation of TLR4/NF-κB signaling and NADPH oxidase.
Lee JH; Sarker MK; Choi H; Shin D; Kim D; Jun HS
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1332-1340. PubMed ID: 30763641
[TBL] [Abstract][Full Text] [Related]
4. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney.
Gorin Y; Block K; Hernandez J; Bhandari B; Wagner B; Barnes JL; Abboud HE
J Biol Chem; 2005 Nov; 280(47):39616-26. PubMed ID: 16135519
[TBL] [Abstract][Full Text] [Related]
5. Argirein alleviates diabetic nephropathy through attenuating NADPH oxidase, Cx43, and PERK in renal tissue.
Hu C; Cong XD; Dai DZ; Zhang Y; Zhang GL; Dai Y
Naunyn Schmiedebergs Arch Pharmacol; 2011 Mar; 383(3):309-19. PubMed ID: 21267711
[TBL] [Abstract][Full Text] [Related]
6. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
[TBL] [Abstract][Full Text] [Related]
7. Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.
Gorin Y; Cavaglieri RC; Khazim K; Lee DY; Bruno F; Thakur S; Fanti P; Szyndralewiez C; Barnes JL; Block K; Abboud HE
Am J Physiol Renal Physiol; 2015 Jun; 308(11):F1276-87. PubMed ID: 25656366
[TBL] [Abstract][Full Text] [Related]
8. NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy.
Jha JC; Banal C; Okabe J; Gray SP; Hettige T; Chow BSM; Thallas-Bonke V; De Vos L; Holterman CE; Coughlan MT; Power DA; Skene A; Ekinci EI; Cooper ME; Touyz RM; Kennedy CR; Jandeleit-Dahm K
Diabetes; 2017 Oct; 66(10):2691-2703. PubMed ID: 28747378
[TBL] [Abstract][Full Text] [Related]
9. Antioxidant and pro-oxidant effects of oil palm (Elaeis guineensis) leaves extract in experimental diabetic nephropathy: a duration-dependent outcome.
Varatharajan R; Sattar MZ; Chung I; Abdulla MA; Kassim NM; Abdullah NA
BMC Complement Altern Med; 2013 Sep; 13():242. PubMed ID: 24074026
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of renal renin-angiotensin system in mouse diabetic nephropathy.
Tamura J; Konno A; Hashimoto Y; Kon Y
Jpn J Vet Res; 2005 Aug; 53(1-2):13-26. PubMed ID: 16190318
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress in diabetic nephropathy.
Kashihara N; Haruna Y; Kondeti VK; Kanwar YS
Curr Med Chem; 2010; 17(34):4256-69. PubMed ID: 20939814
[TBL] [Abstract][Full Text] [Related]
12. The role of adrenomedullin and receptors in glomerular hyperfiltration in streptozotocin-induced diabetic rats.
Hiragushi K; Wada J; Eguchi J; Matsuoka T; Yasuhara A; Hashimoto I; Yamashita T; Hida K; Nakamura Y; Shikata K; Minamino N; Kangawa K; Makino H
Kidney Int; 2004 Feb; 65(2):540-50. PubMed ID: 14717924
[TBL] [Abstract][Full Text] [Related]
13. Renal iron accelerates the progression of diabetic nephropathy in the HFE gene knockout mouse model of iron overload.
Chaudhary K; Chilakala A; Ananth S; Mandala A; Veeranan-Karmegam R; Powell FL; Ganapathy V; Gnana-Prakasam JP
Am J Physiol Renal Physiol; 2019 Aug; 317(2):F512-F517. PubMed ID: 31188032
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin.
Ichihara A; Hayashi M; Kaneshiro Y; Suzuki F; Nakagawa T; Tada Y; Koura Y; Nishiyama A; Okada H; Uddin MN; Nabi AH; Ishida Y; Inagami T; Saruta T
J Clin Invest; 2004 Oct; 114(8):1128-35. PubMed ID: 15489960
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
16. Targeted deletion of B2-kinin receptors protects against the development of diabetic nephropathy.
Tan Y; Keum JS; Wang B; McHenry MB; Lipsitz SR; Jaffa AA
Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1026-35. PubMed ID: 17596525
[TBL] [Abstract][Full Text] [Related]
17. Activation of endothelial NAD(P)H oxidase accelerates early glomerular injury in diabetic mice.
Nagasu H; Satoh M; Kiyokage E; Kidokoro K; Toida K; Channon KM; Kanwar YS; Sasaki T; Kashihara N
Lab Invest; 2016 Jan; 96(1):25-36. PubMed ID: 26552047
[TBL] [Abstract][Full Text] [Related]
18. Suppressing renal NADPH oxidase to treat diabetic nephropathy.
Tojo A; Asaba K; Onozato ML
Expert Opin Ther Targets; 2007 Aug; 11(8):1011-8. PubMed ID: 17665974
[TBL] [Abstract][Full Text] [Related]
19. Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy.
Sedeek M; Callera G; Montezano A; Gutsol A; Heitz F; Szyndralewiez C; Page P; Kennedy CR; Burns KD; Touyz RM; Hébert RL
Am J Physiol Renal Physiol; 2010 Dec; 299(6):F1348-58. PubMed ID: 20630933
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy.
Advani A; Wiggins KJ; Cox AJ; Zhang Y; Gilbert RE; Kelly DJ
Nephrology (Carlton); 2011 Aug; 16(6):573-81. PubMed ID: 21342330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
